

Application No.

: 10/791,270

Confirmation No.:

8940

Applicant

: Masaaki NOMURA, et al.

Filed

: March 3, 2004

TC/A.U.

1615

Examiner Docket No.

: To Be Assigned : 100598.53322US

Customer No.

23911

Title

Pharmaceutical Hard Capsule Containing Inorganic Substance

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents listed on the attached Form PTO-1449 which the Examiner may deem relevant to patentability of the claims of the above-identified application.

## STATEMENT OF RELEVANCE

The relevance of these references to the subject matter of the present invention is given in the sections entitled: <u>Background Art</u> and <u>Disclosure of Invention</u> in the specification of the present invention.

Partial English translations and English abstracts summarizing the disclosures of the publications are submitted herewith.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

Applicant does not waive any right to take any action that would be appropriate to

Application No. 10/791,270 Information Disclosure Statement Filed: July 26, 2004

antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted

Merbert I. Cantor Registration No. 24,392

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844

HIC:ms #329700

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Pape

Work Reduction A Complete if Known Substitute for form 1449A/PTO 10/791,270 **Application Number** INFORMATION DISCLOSURE March 3, 2004 Filing Date Masaaki NOMURA STATEMENT BY APPLICANT First Named Inventor 1615 Art Unit **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 100598.53322US 1 Sheet

Examiner Cite No.1 AA AB AC AD AE	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) JP-61186314-A JP-07252138-A	Publication Date MM-DD-YYYY 08-20-1986	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T <sup>6</sup>
AA AB AC AD	JP-61186314-A		Applicant of Cited Document	_	
AB AC AD			NIPPON ERANKO KK	Appear	AB
AC AD	JP-0/252138-A		NIPPON ERANKO KK		AB
AD		10-03-1995	NIPPON ERANKO KK		AB
	JP-06072862-A	03-15-1994			AB
AE	JP-2552937-B2	08-22-1996	NIPPON ERANKO KK		
	JP-2000202003-A	07-25-2000	SHIONOGI QUALICAPS KK	<del> </del>	AB
AF	JP-08099869-A	04-16-1996	SHIONOGI & CO LTD		AB
AG	JP-2000026282-A	01-25-2000	SHIONOGI & CO LTD		AB
AH	JP-61207387-A	09-13-1986	SUNTORY LTD		AB
Al	JP-63162694-A	07-06-1988	SUNTORY LTD		AB
AJ	JP-60222486-A	11-07-1985	BRISTOL MYERS CO		AB
AK	JP-54119486-A	09-17-1979	CIBA GEIGY AG		AB
AL	JP-06072875-A	03-15-1994	SUNTORY LTD		AB
AM	JP-06128267-A	05-10-1994	SUNTORY LTD		AB
	N	ON PATENT LITE	RATURE DOCUMENTS		
Examiner Cite Initials* No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
AN	TOSHIHIRO OGURA ET AL., "New Cellulose Capsules" Pharm. Tech. (1988) pp. 67-76, 14(3).				Partial
AO	The 32 <sup>nd</sup> Annual Conference of Pharmaceutics, Research Round-Table, Lecture Summery (1995) pp. 46-49.				Partial
АР	68.		tion of Solid Drug Product; Lecture Sum	nmery (1998), pp. 61-	
AQ	YUICHIRO ITO ET AL., Antibio				Partial
AR			on, Ch. 7-1, pp 311-318, Japan.		Partial
AS	Japan Drug Exciplent Diction	Japan Drug Exciplent Dictionary 2000, Japan Pharmaceutical Exciplents Council (8 pages)			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.